Notably, because many of these metabolic disorders often present as co-morbidities in cancer patients, it is feasible that anti-CD36 therapy could also have the potential to simultaneously treat those disorders, adding even further therapeutic value for this emerging class of inhibitors. This evidence concerns the gene CD36 and metabolic disease.